Degarelix Accord (degarelix)
- Region
- 🇪🇺 EU
- Active substance
- degarelix
- Company
- Accord Healthcare S.L.U.
- Status
- Authorised
- Therapeutic area
- Prostatic Neoplasms
- CHMP opinion
- Thu 20 Jul 2023
- EU approval
- Fri 29 Sep 2023
- Designations
- Generic
- Application
- EMEA/H/C/006048
- ATC
- L02BX02
- Official record
- www.ema.europa.eu
Indication
Degarelix Accord is a gonadotrophin releasing hormone (GnRH) antagonist indicated: for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Firmagon Authorised · Ferring Pharmaceuticals A/S
Follow Degarelix Accord
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.